Affimed (NASDAQ:AFMD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Affimed (NASDAQ:AFMD) have been assigned an average rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $7.90.

AFMD has been the topic of a number of recent analyst reports. HC Wainwright cut shares of Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $0.10 price target (down from $11.00) on shares of Affimed in a research note on Tuesday, May 13th. StockNews.com started coverage on shares of Affimed in a research report on Monday. They issued a “sell” rating on the stock. Cantor Fitzgerald lowered shares of Affimed from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Finally, Leerink Partnrs lowered shares of Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th.

Affimed Stock Down 34.9%

NASDAQ:AFMD opened at $0.18 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a fifty-two week low of $0.07 and a fifty-two week high of $8.95. The firm’s fifty day simple moving average is $0.70 and its 200-day simple moving average is $1.36.

Institutional Investors Weigh In On Affimed

An institutional investor recently raised its position in Affimed stock. Intellectus Partners LLC raised its position in Affimed (NASDAQ:AFMD) by 34.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,414 shares of the biopharmaceutical company’s stock after purchasing an additional 32,053 shares during the period. Intellectus Partners LLC owned about 0.79% of Affimed worth $150,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.